nach oben

Erschienen in:

19.10.2018 | Case Report

Occurrence of hepatocellular carcinoma 24 years after successful interferon therapy in a patient with chronic hepatitis C: a case report

Erschienen in: Clinical Journal of Gastroenterology | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

An 82-year-old man presented with hepatocellular carcinomas (HCCs) 24 years after achieving a sustained virological response (SVR) to an interferon for hepatitis C. His hepatic fibrosis stage was F1 when he was treated at 58 years. He was followed-up by annual blood tests and abdominal ultrasonography or computed tomography. After the IFN treatment, he had drunk approximately 100 g of ethanol. Serum aspartate aminotransferase and gamma-glutamyl transpeptidase levels had been elevated since 2012. To investigate the possible factors that affect hepatocarcinogenesis over 10 years after achieving an SVR, we reviewed the literature. Of 39 reported patients, 26, as well as ours, had one or more lifestyle-related factors, including body mass index ≥ 25 kg/m², diabetes mellitus, impaired glucose tolerance, hepatosteatosis, or alcohol consumption. In our patient, aging and daily alcohol consumption might have triggered the development of HCCs.

Tada T, Kumada T, Toyoda H, et al. Viral eradication reduces all-cause mortality, including non-liver-related disease, in patients with progressive hepatitis C virus-related fibrosis. J Gastroenterol Hepatol. 2017;32:687–94.CrossRefPubMed

Makiyama A, Itoh Y, Kasahara A, et al. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer. 2004;101:1616–22.CrossRefPubMed

El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virological response in veterans with hepatitis C virus infection. Hepatology. 2016;64:130–37.CrossRefPubMed

Iwasaki Y, Takaguchi K, Ikeda H, et al. Risk factors for hepatocellular carcinoma in hepatitis C patients with sustained virologic response to interferon therapy. Liver Int. 2004;24:603–10.CrossRefPubMed

Igarashi G, Endo T, Sawada N, et al. Development of hepatocellular carcinoma in chronic hepatitis c patients 20 years after achieving a sustained virological response with interferon therapy: a report of two cases. J Gen Fam Med. 2015;16:199–203.CrossRef

Okabe J, Fukuda K, Iwamoto T, et al. A case of cirrhosis with hepatitis C virus infection developing hepatocellular carcinoma 20 years after achieving sustained virological response to interferon therapy. Kanzo (Acta Hepatol Jpn). 2016;57:27–33 (in Japanese, abstract in English).CrossRef

Nakayama H, Iketani S, Okamoto D, et al. Long-term prognosis of patients with chronic hepatitis C who developed hepatocellular carcinoma after a sustained response to interferon therapy. Iwaki Kyoritsu Byoin Ihou (J Iwaki Kyoritsu Gen Hosp). 2013;34:12–21 (in Japanese).

Harai S, Kuratomi N, Fukazawa Y, et al. A case of hepatocellular carcinoma with portal vein tumor thrombosis and bone metastasis developed 20 years after successful interferon therapy to hepatitis C. Yamanashi Kenritsu Chuo Byoin Nenpo (J Yamanashi-ken Central Hosp. 2015; 41:68–70 (in Japanese).

Hirohata Y, Yoh Y, Nakamura Y, Kato T, Okamura R. Surgical treatment for hepatocellular carcinoma in a chronic hepatitis C patient 20 years after achieving a sustained virological response. Nippon Shokaki Geka Gakkai Zasshi (Jpn J Gastroenterol Surg). 2017;50:528–34 (in Japanese, abstract in English).CrossRef

10.

Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289–93.CrossRefPubMed

11.

Kuno A, Ikehara Y, Tanaka Y, et al. A serum “sweet-doughnut” protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep. 2013;3:1065.CrossRefPubMedPubMedCentral

12.

Nagata H, Nakagawa M, Nishimura-Sakurai Y, et al. Serial measurement of Wisteria floribunda agglutinin positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy. Hepatol Int. 2016;10:956–64.CrossRefPubMed

13.

Sato T, Okada M, Masumoto A, Takeda N. A case of surgical treatment for hepatocellular carcinoma occurred 10 years after a successful interferon therapy in a patient with chronic hepatitis C. Rinsho to Kenkyu (Jpn J Clin Exp). 2005;82:342–43. (in Japanese).

14.

Kobayashi M, Suzuki M, Yamada N, et al. A case of hepatocellular carcinoma developed ten years after successful interferon therapy for chronic hepatitis C. Sei Marianna Ika Daigaku Zasshi (St Marianna Med J). 2006;34:115–23 (in Japanese, abstract in English).

15.

Sugunami F, Tomiyama Y, Ohmoto K, et al. Hepatocellular carcinoma occurring after 11 year-long sustained viral response to interferon therapy for chronic hepatitis C. Nippon Shokakibyo Gakkai Zasshi (Jpn J Soc Gastroenterol). 2007;104:809–14. (in Japanese, abstract in English).

16.

Kimura Y, Tsuji K, Matsui T, et al. A case of synchronous double cancer of liver metastasis of thymoma and hepatocellular carcinomas, 10 years after achieving sustained virological response treated with peginterferon/ribavirin in chronic hepatitis C virus infection. Kanzo (Acta Hepatol Jpn). 2016;57:252–59 (in Japanese, abstract in English).CrossRef

17.

Hanaoka J, Shimada M, Ikegami T, et al. A case of surgical treatment for hepatocellular carcinoma that developed in a chronic hepatitis C patient who had shown sustained virological response to interferon 11 years before. Kanzo (Acta Hepatol Jpn). 2008;49:248–54 (in Japanese, abstract in English).CrossRef

18.

Nojiri K, Sugimoto K, Shiraki K, et al. Development of hepatocellular carcinoma in patients with chronic hepatitis C more than 10 years after sustained virological response to interferon therapy. Oncol Lett. 2010;1:427–30.CrossRefPubMedPubMedCentral

19.

Ito Y, Yamamoto N, Nakata R, et al. Delayed development of hepatocellular carcinoma during long-term follow-up after eradication of hepatitis C virus by interferon therapy. World J Gastroenterol. 2005;11:7218–21.CrossRefPubMedPubMedCentral

20.

Kawano Y, Egami K, Sasajima K, et al. A hepatocellular carcinoma developed following 12 years from sustained virologic response to interferon therapy in a patient with hepatitis C. Kanzo (Acta Hepatol Jpn). 2007;48:48–56 (in Japanese, abstract in English).CrossRef

21.

Hayashi T, Tamori A, Nishikawa M, et al. Differences in molecular alterations of hepatocellular carcinoma between patients with a sustained virological response and those with hepatitis C virus infection. Liver Int. 2009;29:126–32.CrossRefPubMed

22.

Sanefuji K, Kayashima H, Iguchi T, et al. Characterization of hepatocellular carcinoma developed after achieving sustained virological response to interferon therapy for hepatitis C. J Surg Oncol. 2009;99:32–7.CrossRefPubMed

23.

Tsumura T, Takaki S, Aikata H, et al. A case of double cancer of the liver, cholangiocarcinoma and hepatocellular carcinoma detected in a patient with hepatitis C 13 years after diminution of HCV-RNA by interferon treatment. Nippon Shokakibyo Gakkai Zasshi (Jpn J Soc Gastroenterol). 2009;106:674–583 (in Japanese, abstract in English).

24.

Yagura M, Tanaka A, Kamitsukasa H. A case of hepatocellular carcinoma who cleared hepatitis C virus with interferon therapy 13 years ago. Kanzo (Acta Hepatol Jpn). 2009;50:238–43 (in Japanese, abstract in English).CrossRef

25.

Mashitani T, Yoshiji H, Yamazaki M, et al. Development of hepatocellular carcinoma in a patient 13 years after sustained virological response to interferon against chronic hepatitis C: a case report. Cases J. 2009;2:18.CrossRefPubMedPubMedCentral

26.

Bertolini E, Bassi F, Fornaciari G. Deveopment of hepatocellular carcinoma in a non-cirrhotic, long-term responder to antiviral therapy, chronic hepatitis C patient: what kind of surveillance? Ann Gastroenterol. 2013;26:80–3.PubMedPubMedCentral

27.

Watanabe E, Koizumi Y, Hirooka M, et al. Hepatocellular carcinoma in a chronic hepatitis C patient 15 years after achieving a sustained virological response. Kanzo (Acta Hepatol Jpn). 2012;53:763–68 (in Japanese, abstract in English).CrossRef

28.

Higuchi R, Yasuda H, Koda K, et al. Hepatocellular Carcinoma Development in Hepatitis-C-Sustained Virological Response to Interferon-Based Therapy After 15-Year Follow-Up. Nippon Gekakei Rengo Gakkaishi (J Jpn Coll Surgeons). 2011;36:66–71 (in Japanese, abstract in English).CrossRef

29.

Takeuchi N, Tada H, Nishida Y, et al. Rapid growing hepatocellular carcinoma in a patient with chronic hepatitis C after 16 years of a sustained and complete response to interferon therapy. Kan Tan Sui. 2011;63:699–705 (in Japanese).

30.

Saito M, Seo Y, Yano Y, et al. Development of a hepatocellular carcinoma in a chronic hepatitis C patient 18 years after achieving a sustained virological response to interferon therapy: case report and literature review. Clin J Gastroenterol. 2012;5:119–26.CrossRefPubMed

31.

Ohshima K, Oba N, Kyoden Y, Iseki J, et al. A case of surgical treatment for hepatocellular carcinoma detected in a patient with chronic hepatitis C who had shown sustained virological response (SVR) to interferon 19 years before. Liver Cancer (Tokyo). 2012;18:23–35 (in Japanese, abstract in English).

32.

Toyoda H, Tada T, Takaguchi K, et al. Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan. J Viral Hepat. 2017;24:472–76.CrossRefPubMed

33.

Asahina Y, Tsuchiya K, Nishimura T, et al. alpha-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology. 2013;58:1253–62.CrossRefPubMed

34.

Nirei K, Matsumura H, Kumakawa M, et al. Steatosis influences the clinical profiles and long-term outcomes of interferon-treated chronic hepatitis C and liver cirrhosis patients. Int J Med Sci. 2017;14:45–52.CrossRefPubMedPubMedCentral

35.

Nanba S, Ikeda F, Baba N, et al. Association of hepatic oxidative stress and iron dysregulation with HCC development after interferon therapy in chronic hepatitis C. J Clin Pathol. 2016;69:226–33.CrossRefPubMed

36.

Whitfield JB, Zhu G, Heath AC, et al. Effects of alcohol consumption on indices of iron stores and of iron stores on alcohol intake markers. Alcohol Clin Exp Res. 2001;25:1037–45.CrossRefPubMed

37.

Ikeda K, Marusawa H, Osaki Y, et al. Antibody to hepatitis B core antigen and risk for hepatitis C–related hepatocellular carcinoma: a prospective study. Ann Int Med. 2007;146:649–56.CrossRefPubMed

38.

Kusumoto S, Tanaka Y, Mizokami M, et al. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol. 2009;90:13–23.CrossRefPubMed

Titel: Occurrence of hepatocellular carcinoma 24 years after successful interferon therapy in a patient with chronic hepatitis C: a case report
Publikationsdatum: 19.10.2018
Erschienen in: Clinical Journal of Gastroenterology / Ausgabe 2/2019
Print ISSN: 1865-7257
Elektronische ISSN: 1865-7265
DOI: https://doi.org/10.1007/s12328-018-0915-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

Caroli syndrome: a clinical case with detailed histopathological analysis

A case of unique endoscopic findings of intestinal endometriosis exposed to the mucosa: aggregation of papillary protruded bulges from the submucosal elevation of the rectum

Endoscopic ultrasound-guided treatment of pancreatic fluid collections with lumen apposing metallic stents: lessons learned

Current indications and yield of endoscopic ultrasound and ancillary techniques in pancreatic cystic neoplasms

A case of chronic pancreatitis exacerbation associated with pancreatic arteriovenous malformation: a case report and literature review